2-羟基-4-甲基吡啶-3-甲腈 | 93271-59-1

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-羟基-4-甲基吡啶-3-甲腈
• 中文别名: 3-氰基-4-甲基-2-吡啶酮
• 英文名称: 4-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile
• 英文别名: 3-cyano-4-methyl-2-pyridone；2-Hydroxy-4-methylpyridine-3-carbonitrile；4-methyl-2-oxo-1H-pyridine-3-carbonitrile
• CAS: 93271-59-1
• 化学式: C₇H₆N₂O
• mdl: MFCD09834635
• 分子量: 134.137
• InChiKey: XSJRLWNOZDULKJ-UHFFFAOYSA-N

物化性质

• 熔点：
  234.7-236.1 °C
• 沸点：
  337.7±35.0 °C(Predicted)
• 密度：
  1.20±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  52.9
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  室温且干燥环境中保存。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Hydroxy-4-methylpyridine-3-carbonitrile
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Hydroxy-4-methylpyridine-3-carbonitrile
CAS number: 93271-59-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H6N2O
Molecular weight: 134.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-羟基-4-甲基吡啶-3-甲腈 在 sodium hypochlorite 、 硫酸 、 水 、 sodium hydroxide 、 三溴氧磷 作用下， 以 乙醇 、 水 、 甲苯 为溶剂， 反应 24.0h， 生成 2-溴-3-氨基-4-甲基吡啶
  参考文献：
  名称：

  一种2-异丙基-3-氨基-4-甲基吡啶的合成方法

  摘要：

  本发明公开了一种2‑异丙基‑3‑氨基‑4‑甲基吡啶的制备方法，所述制备方法的具体步骤为：(1)3‑氰基‑4‑甲基‑2‑吡啶酮与三溴氧磷反应，得到2‑溴代‑3‑氰基‑4‑甲基吡啶；(2)2‑溴代‑3‑氰基‑4‑甲基吡啶用浓硫酸水解，得到2‑溴‑4‑甲基烟酰胺；(3)2‑溴‑4‑甲基烟酰胺与次氯酸钠溶液在氢氧化钠条件下反应，发生霍夫曼重排，得到2‑溴‑3‑氨基‑4‑甲基吡啶；(4)2‑溴‑3‑氨基‑4‑甲基吡啶在含铁或镍的催化剂作用下，与异丙基格式试剂反应，得到2‑异丙基‑3‑氨基‑4‑甲基吡啶。本发明成本低廉，操作简单，是合成2‑异丙基‑3‑氨基‑4‑甲基吡啶的新方法。

  公开号：

  CN113354578A
• 作为产物：
  描述：

  2-氰基-3-甲基丁烯酸乙酯 在 氨 作用下， 反应 6.0h， 生成 2-羟基-4-甲基吡啶-3-甲腈
  参考文献：
  名称：

  Acetals of lactams and acid amides. 42. Cyclization of dienamino esters, dienamino nitriles, and acylamidines to pyridine derivatives

  摘要：

  DOI：

  10.1007/bf00508675

文献信息

• Discovery of 8-Amino-Substituted 2-Phenyl-2,7-Naphthyridinone Derivatives as New c-Kit/VEGFR-2 Kinase Inhibitors
  作者：Haiyan Sun、Linsheng Zhuo、Huan Dong、Wei Huang、Nengfang She

  DOI：10.3390/molecules24244461

  日期：——

  scaffold has been proposed as a novel lead structure of MET inhibitors by our group. To broaden the application of this new scaffold, a series of 8-amino-substituted 2-phenyl-2,7-naphthyridin-1(2H)-one derivatives were designed and synthesized. Preliminary biological screening resulted in the discovery of a new lead of c-Kit and VEGFR-2 kinase inhibitors. Compound 9k exhibited excellent c-Kit inhibitory activity

  我们小组已提出 2,7-萘啶酮支架作为 MET 抑制剂的新型先导结构。为了扩大这种新支架的应用，设计并合成了一系列 8-氨基取代的 2-苯基-2,7-萘啶-1(2H)-one 衍生物。初步生物筛选导致发现了 c-Kit 和 VEGFR-2 激酶抑制剂的新先导。化合物9k表现出优异的c-Kit抑制活性，IC50值为8.5nM，即比化合物3(IC50为329.6nM)强38.8倍。此外，化合物10l 和10r 表现出良好的VEGFR-2 抑制活性，IC50 值分别为56.5 和31.7 nM，即它们比化合物3（IC50 为279.9 nM）强5.0-8.8 倍。分子对接实验进一步深入了解新先导化合物与 c-Kit 和 VEGFR-2 激酶的结合相互作用。在这项研究中，8-氨基取代的 2-苯基-2,7-naphthyridin-1(2H)-one 支架被确定为 c-Kit 和 VEGFR-2 激酶抑制剂的新先导结构。
• [EN] HETEROCYCLIC COMPOUNDS AS EP4 RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS EN TANT QU'ANTAGONISTES DES RÉCEPTEURS CCR4
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2016021742A1

  公开（公告）日：2016-02-11

  The present invention provides a compound represented by the formula (1) : wherein each symbol is as defined in the specification or a salt thereof has an EP4 receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of EP4 receptor associated diseases (e.g., rheumatoid arthritis, aortic aneurysm, endometriosis, ankylosing spondylitis, inflammatory breast cancer etc.) and the like.

  本发明提供了一种化合物，其化学式表示为（1）：其中每个符号如规范中定义或其盐具有EP4受体拮抗作用，并且可用作预防或治疗与EP4受体相关疾病（例如类风湿性关节炎、主动脉瘤、子宫内膜异位症、强直性脊柱炎、炎性乳腺癌等）等的药剂。
• 一类2,7-萘啶-1(2H)-酮的合成方法
  申请人：江苏先声药物研究有限公司

  公开号：CN103159757B

  公开（公告）日：2016-04-20

  本发明公开了一类结构如式（I）所示的2,7-萘啶-1(2H)-酮的合成方法。这类化合物是合成作为酪氨酸激酶抑制剂或丝氨酸-苏氨酸激酶抑制剂的一类2,7-萘啶衍生物的关键中间体。
• [EN] HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS<br/>[FR] DÉRIVÉS DE CARBOXAMIDE HÉTÉROAROMATIQUES EN TANT QU'INHIBITEURS DE LA KALLICRÉINE PLASMATIQUE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2021160718A1

  公开（公告）日：2021-08-19

  Heteroaromatic carboxamides of formula (I), wherein Y, R, and Ar are as defined in the description and the claims, and pharmaceutically acceptable salts thereof can be used in methods for the treatment of diseases which can be influenced by the inhibition of plasma kallikrein.

  式(I)中的杂环芳香族羧酰胺，其中Y、R和Ar如描述和权利要求中定义，并且其药学上可接受的盐可用于治疗受血浆激肽酶抑制影响的疾病的方法。
• [EN] VOLTAGE-GATED SODIUM CHANNEL BLOCKERS<br/>[FR] BLOQUEURS DES CANAUX SODIQUES VOLTAGE-DÉPENDANTS
  申请人：GLAXO GROUP LTD

  公开号：WO2013006596A1

  公开（公告）日：2013-01-10

  In general, the present invention relates to uses of voltage-gated sodium channel blocker compounds,, which include corresponding precursors, intermediates, monomers and dimers, corresponding pharmaceutical compositions, compound preparation and treatment methods for respiratory and respiratory tract diseases. In particular, the present invention also relates to methods and uses for treatment of respiratory or respiratory tract diseases, which comprises administering to a subject in need thereof an effective amount of a compound of the present invention.

  一般而言，本发明涉及使用电压门控钠通道阻滞剂化合物，包括相应的前体、中间体、单体和二聚体，相应的药物组合物，化合物制备和治疗方法，用于呼吸和呼吸道疾病。具体而言，本发明还涉及用于治疗呼吸或呼吸道疾病的方法和用途，包括向需要的受试者施用本发明化合物的有效量。